(Q41130517)

27 September 2017

Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions (English)

1 reference

27 September 2017

1 reference

4

Antonia M Joussen

1 reference

27 September 2017

Anja Lux

1

1 reference

27 September 2017

Helene Llacer

series ordinal

2

1 reference

27 September 2017

Florian M A Heussen

series ordinal

3

1 reference

27 September 2017

language of work or name

English

0 references

publication date

30 May 2007

1 reference

British Journal of Ophthalmology

27 September 2017

1 reference

27 September 2017

91

1 reference

27 September 2017

10

1 reference

27 September 2017

1318-1322

1 reference

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Ranibizumab for neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Pegaptanib for neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000982

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

4 November 2018

1 reference

12 December 2020

New visual acuity charts for clinical research

1 reference

12 December 2020

[A new reading chart for simultaneous determination of reading vision and reading speed]

1 reference

12 December 2020

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study

1 reference

12 December 2020

[Intravitreal bevacizumab for neovascular age-related macular degeneration]

1 reference

12 December 2020

Identifiers

DOI

10.1136/BJO.2006.113902

1 reference

27 September 2017

1 reference

27 September 2017

PubMed publication ID

17537784

1 reference